ClinicalTrials.Veeva

Menu

Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies (GADO-ICH)

C

Centre Hospitalier Universitaire de Nīmes

Status

Not yet enrolling

Conditions

Cerebral Hemorrhage
Acute Lobar Haematoma

Treatments

Other: None, pure observational study

Study type

Observational

Funder types

Other

Identifiers

NCT06781034
Local/2024/TP-02

Details and patient eligibility

About

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment.

Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis.

An equivalent marker has also been described in gadolinium-enhanced MRI.

By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.

Enrollment

128 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;
  • Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.

Exclusion criteria

  • Patient refusing to participate

Trial design

128 participants in 1 patient group

patients with acute lobar and deep haematoma
Description:
None, pure observational study
Treatment:
Other: None, pure observational study

Trial contacts and locations

0

Loading...

Central trial contact

Teodora PARVU

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems